How does Mounjaro® (tirzepatide) actually work for type 2 diabetes? Mounjaro® (tirzepatide) has become an important treatment option for type 2 diabetes—but what is it actually doing inside the body? In this Rehealthify Diabetes Corner episode, we break down how tirzepatide works, how it affects insulin and blood sugar, why it targets both GIP and GLP-1 receptors, how it affects the digestive system, common side effects, important safety warnings, dosing considerations, and what to discuss with your healthcare professional. Rather than simply focusing on the medication itself, we'll look at the body's communication system—including the pancreas, liver, stomach, intestines, insulin, glucagon, and blood glucose—to explain why tirzepatide can help improve blood sugar control. CHAPTERS 00:00 — Mounjaro & Type 2 Diabetes: The Big Picture 00:15 — Inside the Body: The Blood Sugar System 00:30 — What Is Mounjaro (Tirzepatide)? 00:50 — Why Mounjaro Is Used for Type 2 Diabetes 01:10 — Important Safety Risks & Warnings 02:00 — Dosing & Why More Isn't Always Better 02:10 — How the Body Communicates About Blood Sugar 03:10 — How Tirzepatide Helps Regulate Blood Glucose 04:00 — Monitoring & Questions to Discuss With Your Healthcare Professional 04:40 — Mounjaro: Important Considerations 05:00 — Summary: What to Know About Tirzepatide Mounjaro® is a registered trademark of Eli Lilly and Company. Rehealthify is an independent health-information and education channel and is not affiliated with, sponsored by, or endorsed by Eli Lilly and Company. IMPORTANT HEALTH INFORMATION This video is for educational and informational purposes only and is not medical advice. Mounjaro® (tirzepatide) is a prescription medication. It is important to discuss your individual health history, medications, risks, benefits, and treatment options with a qualified healthcare professional. Mounjaro has a boxed warning regarding the risk of thyroid C-cell tumors. Tirzepatide caused thyroid C-cell tumors in rats, and it is not known whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Mounjaro is contraindicated in people with a personal or family history of MTC or in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Mounjaro can also be associated with other important risks and adverse reactions, including gastrointestinal adverse reactions, pancreatitis, gallbladder problems, hypoglycemia when used with certain other diabetes medications, and other potentially serious complications. The full prescribing information should be reviewed with a healthcare professional. Do not start, stop, change, or adjust a prescription medication based solely on information presented in this video. REFERENCES & SOURCES U.S. Food and Drug Administration / Eli Lilly — Mounjaro® (tirzepatide) Prescribing Information Mounjaro Prescribing Information MedlinePlus — Tirzepatide Injection: Drug Information MedlinePlus: Tirzepatide Injection National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — Type 2 Diabetes NIDDK: Type 2 Diabetes NIDDK — Insulin Resistance & Prediabetes NIDDK: Insulin Resistance & Prediabetes Information and prescribing recommendations can change. Always refer to the most current prescribing information and consult a qualified healthcare professional for individual medical guidance. FOLLOW REHEALTHIFY Subscribe to Rehealthify for evidence-based health information explained clearly—without the medical jargon. Rehealthify Diabetes Corner explores diabetes, medications, metabolism, blood sugar, weight management, and the science behind modern diabetes care. Subscribe for more health education: New videos covering diabetes medications, type 2 diabetes, GLP-1 medications, GIP/GLP-1 medications, blood sugar, insulin resistance, and more. #Mounjaro #Tirzepatide #Type2Diabetes #Diabetes #DiabetesMedication #BloodSugar #InsulinResistance #GLP1 #GIP #DiabetesEducation #Rehealthify